The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
Abstract
OBJECTIVE: In the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial involving 7,020 patients with type 2 diabetes and established cardiovascular (CV) disease, empagliflozin given in addition to standard of care reduced the risk of CV death by 38% versus placebo (hazard ratio [HR] 0.62 [95% CI 0.49, 0.77]). This exploratory mediation analysis assesses the extent to which treatment group differences in covariates during the trial contributed to CV death risk reduction with empagliflozin. RESEARCH DESIGN AND METHODS: Effects of potential mediators, identified post hoc, on the HR for CV death with empagliflozin versus placebo were analyzed by Cox regression models, with treatment group adjusted for the baseline value of the variable and its change from baseline or updated mean (i.e., considering all prior values), each as a time-dependent covariate. HRs were compared with a model without adjustment for covariates. Multivariable analyses also were performed. RESULTS: Changes in hematocrit and hemoglobin mediated 51.8% and 48.9%, respectively, of the effect of empagliflozin versus placebo on the risk of CV death on the basis of changes from baseline, with similar results in analyses on the basis of updated means. Smaller mediation effects (maximum 29.3%) were observed for uric acid, fasting plasma glucose, and HbA1c. In multivariable models, which incorporated effects of empagliflozin on hematocrit, fasting glucose, uric acid, and urine albumin:creatinine ratio, the combined changes from baseline provided 85.2% mediation, whereas updated mean analyses provided 94.6% mediation of the effect of empagliflozin on CV death. CONCLUSIONS: In this exploratory analysis from the EMPA-REG OUTCOME trial, changes in markers of plasma volume were the most important mediators of the reduction in risk of CV death with empagliflozin versus placebo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“both have been identified as important determinants of the heart failure benefits of these drugs in trials of patients with type 2 diabetes.”
From Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial (2021) · cites this paper as [32]
In the citing paper
“Those that appear particularly plausible include effects on volume status, natriuresis, expansion of red blood cell mass, and myocardial energetics (34,36,59,62,64).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [59]
In the citing paper
“Thus, the mechanisms by which SGLT2 inhibitors reduce the risk for HF are not attributable to improved glycemic control (59).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [59]
Citations
Cites
Baron, R. M., & Kenny, D. A. (1986) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.51.6.1173 · Cited by 91,532 · cited 2×
“A traditional mediation analysis as originally proposed by Baron and Kenny (12) was used, taking the time-dynamic evolvement of both the potential mediators and the outcome CV death into account.”
Method(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citation10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Introduction to Statistical Mediation Analysis
MacKinnon, D. P. (2012) · doi:10.4324/9780203809556 · Cited by 5,618
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Self-citationUric Acid and Cardiovascular Risk
Feig, D. I., Kang, D.-H., & Johnson, R. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0800885 · Cited by 2,440
Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
Self-citationCherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329 · cited 1×
“Moreover, only variablesmeasured during the trial could be examined, and in addition to the potential mediators we investigated, other variables such as reductions in glomerular hyperfiltration (35), reductions in arterial stiffness and vascular resistance (36), direct cardiac effects through reductions in myocardial…”
BackgroundSelf-citationLow Wang, C. C., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016) · Circulation · doi:10.1161/circulationaha.116.022194 · Cited by 1,155 · cited 1×
“Therefore, many participants in this trial likely had unrecognized left ventricular dysfunction, particularly diastolic dysfunction, which may eventually lead to clinical heart failure with preserved ejection fraction (25).”
BackgroundFitchett, D., Zinman, B., Wanner, C., Lachin, J. M., Hantel, S., Salsali, A., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv728 · Cited by 907
Self-citationDapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B., & List, J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12127 · Cited by 837 · cited 1×
“Increased erythropoietin and a median 7% increase in red blood cell mass, measured with (51)Cr-labeled erythrocytes, were observed in a small study (n = 30) of the SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes (26).”
BackgroundFerrannini, E., Baldi, S., Frascerra, S., Astiarraga, B., Heise, T., Bizzotto, R., Mari, A., Pieber, T. R., & Muscelli, E. (2016) · Diabetes · doi:10.2337/db15-1356 · Cited by 712
Self-citationBaartscheer, A., Schumacher, C. A., Wüst, R. C. I., Fiolet, J. W. T., Stienen, G. J. M., Coronel, R., & Zuurbier, C. J. (2017) · Diabetologia · doi:10.1007/s00125-016-4134-x · Cited by 661 · cited 1×
“Moreover, only variablesmeasured during the trial could be examined, and in addition to the potential mediators we investigated, other variables such as reductions in glomerular hyperfiltration (35), reductions in arterial stiffness and vascular resistance (36), direct cardiac effects through reductions in myocardial…”
BackgroundGrempler, R., Thomas, L., Eckhardt, M., Himmelsbach, F., Sauer, A., Sharp, D. E., Bakker, R. A., Mark, M., Klein, T., & Eickelmann, P. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01517.x · Cited by 608 · cited 1×
“Empagliflozin is a selective inhibitor of SGLT2 in the proximal tubule of the kidney (20).”
BackgroundImproving caregiver well-being delays nursing home placement of patients with Alzheimer disease
Mittelman, M. S., Haley, W. E., Clay, O. J., & Roth, D. L. (2006) · Neurology · doi:10.1212/01.wnl.0000242727.81172.91 · Cited by 602
Mudaliar, S., Alloju, S., & Henry, R. R. (2016) · Diabetes Care · doi:10.2337/dc16-0542 · Cited by 571 · cited 1×
“Moreover, only variablesmeasured during the trial could be examined, and in addition to the potential mediators we investigated, other variables such as reductions in glomerular hyperfiltration (35), reductions in arterial stiffness and vascular resistance (36), direct cardiac effects through reductions in myocardial…”
BackgroundChilton, R., Tikkanen, I., Cannon, C. P., Crowe, S., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12572 · Cited by 507 · cited 1×
“Moreover, only variablesmeasured during the trial could be examined, and in addition to the potential mediators we investigated, other variables such as reductions in glomerular hyperfiltration (35), reductions in arterial stiffness and vascular resistance (36), direct cardiac effects through reductions in myocardial…”
BackgroundSelf-citationChino, Y., Samukawa, Y., Sakai, S., Nakai, Y., Yamaguchi, J., Nakanishi, T., & Tamai, I. (2014) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1909 · Cited by 389 · cited 1×
“Empagliflozin reduces uric acid, possibly as a result of the effect of increased glucose concentration on glucose transporter 9 in the basolateral membrane of the proximal tubule and resulting increaseduricosuria (22,32).”
BackgroundThe Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group (2015) · Diabetes · doi:10.2337/db14-0930 · Cited by 333
Sattar, N., McLaren, J., Kristensen, S. L., Preiss, D., & McMurray, J. J. (2016) · Diabetologia · doi:10.1007/s00125-016-3956-x · Cited by 309 · cited 2×
“Moreover, only variablesmeasured during the trial could be examined, and in addition to the potential mediators we investigated, other variables such as reductions in glomerular hyperfiltration (35), reductions in arterial stiffness and vascular resistance (36), direct cardiac effects through reductions in myocardial…”
BackgroundHeise, T., Seewaldt‐Becker, E., Macha, S., Hantel, S., Pinnetti, S., Seman, L., & Woerle, H. J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12073 · Cited by 273 · cited 1×
“Inhibition of SGLT2 by empagliflozin leads to reduced renal glucose reabsorption and increased urinary glucose excretion (21).”
BackgroundSelf-citationZinman, B., Inzucchi, S. E., Lachin, J. M., Wanner, C., Ferrari, R., Fitchett, D., Bluhmki, E., Hantel, S., Kempthorne-Rawson, J., Newman, J., et al. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-102 · Cited by 239
Self-citationFerrannini, E., Baldi, S., Frascerra, S., Astiarraga, B., Barsotti, E., Clerico, A., & Muscelli, E. (2017) · Diabetes Care · doi:10.2337/dc16-2724 · Cited by 181 · cited 1×
“In a larger study, a mean increase in erythropoietin of 30–40% was observed 4 weeks after initiating empagliflozin, which may be related to changes in blood flow between the renal cortex and themedulla (27).”
BackgroundSelf-citationMarx, N., & McGuire, D. K. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw110 · Cited by 165
Potential mediators of the mortality reduction with zoledronic acid after hip fracture
Colón-Emeric, C. S., Mesenbrink, P., Lyles, K. W., Pieper, C. F., Boonen, S., Delmas, P., Eriksen, E. F., & Magaziner, J. (2010) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090704 · Cited by 159
Odden, M. C., Amadu, A.-R., Smit, E., Lo, L. J., & Peralta, C. A. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.04.024 · Cited by 154 · cited 1×
“Serum uric acid has been associated with an increased risk of CV death (33), but evidence is limited regarding the CV benefits of reducing uric acid (34), especially within the normal range and/or to the small degree observed in the EMPA-REG OUTCOME trial.”
BackgroundRajasekeran, H., Lytvyn, Y., & Cherney, D. Z. I. (2016) · Kidney International · doi:10.1016/j.kint.2015.12.038 · Cited by 129 · cited 1×
“The resulting decrease in circulatory load, especially reduced ventricular filling pressures and cardiac workload, could be an importantmechanismbehind themortality benefits seen with empagliflozin (5,9).”
BackgroundHeise, T., Jordan, J., Wanner, C., Heer, M. A., Macha, S., Mattheus, M., Lund, S. S., Woerle, H. J., & Broedl, U. C. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.09.001 · Cited by 96 · cited 2×
“Treatment with empagliflozin reduces volume and sodium load through its glucuretic, diuretic, and natriuretic properties (22,23).”
BackgroundSelf-citationHeise, T., Jordan, J., Wanner, C., Heer, M. A., Macha, S., Mattheus, M., Lund, S. S., Woerle, H. J., & Broedl, U. C. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.08.008 · Cited by 59
Self-citationGlucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?
Giorgino, F., Home, P., & Tuomilehto, J. O. (2016) · Diabetes Care · doi:10.2337/dcs15-3023 · Cited by 57
EMPA-REG: Glucose excretion and lipid mobilization – not storage – saves lives
Jørgensen, N. B., Pedersen, J., & Vaag, A. A. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.02.015 · Cited by 10
Effect of Empagliflozin on Albuminuria in Patients with Type 2 Diabetes and High Cardiovascular Risk
Pfarr, E., Zinman, B., Silvio, E. I., Koitka‐Weber, A., Maximilian, V. E., Lambers, H. H. J., David, C., & Wanner, C. (2017) · 日本腎臓学会誌 · Cited by 1
Self-citation
Research works printed but not linked: 2
- Fitchett, Further exploration of the cardiovascular mortality reduction with empagliflozin in patients with type 2 diabetes and cardiovascular disease in EMPA-REG OUTCOME, J Am Coll Cardiol
- Boehringer Ingelheim. Empagliflozin (Jardiance®) to be studied in chronic kidney disease. 2017. Available from https://www.boehringer-ingelheim.com/press-release/empagliflozin-be-studied-chronic-kidney-disease. Accessed 6 September 2017
Cited by
Zannad, F., Ferreira, J. P., Pocock, S. J., Anker, S. D., Butler, J., Filippatos, G., Brueckmann, M., Ofstad, A. P., Pfarr, E., Jamal, W., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31824-9 · Cited by 1,408
McGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.4511 · Cited by 1,235
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Verma, S., & McMurray, J. J. V. (2018) · Diabetologia · doi:10.1007/s00125-018-4670-7 · Cited by 999
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
Cowie, M. R., & Fisher, M. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0406-8 · Cited by 784
Metadata
- Authors
- Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., Hantel, S., Bluhmki, E., & Lachin, J. M.
- Affiliations
- Yale University (US)
- Mount Sinai Hospital (CA)
- St. Michael's Hospital (CA)
- Universitätsklinikum Würzburg (DE)
- Istituto di Fisiologia Clinica (IT)
- University of Freiburg (DE)
- Boehringer Ingelheim (Norway) (NO)
- Boehringer Ingelheim (Germany) (DE)
- George Washington University (US)
- Corresponding author
- Inzucchi, Silvio E.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-12-04
- Volume
- 41
- Issue
- 2
- Pages
- 356-363
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2772204795
- Cited by
- 740
- References
- 33
- Citations by year
- 2026: 33 · 2025: 48 · 2024: 71 · 2023: 83 · 2022: 103 · 2021: 109 · 2020: 139 · 2019: 96 · 2018: 56
- FWCI
- 62.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Eisai
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- empagliflozin, cardiovascular mortality, mediation analysis, type 2 diabetes, EMPA-REG OUTCOME trial, hematocrit, hemoglobin, plasma volume, uric acid, fasting blood glucose, HbA1c, urine albumin-creatinine ratio, SGLT2 inhibitors
- MeSH terms
- Adult, Aged, Benzhydryl Compounds, Blood Glucose, Cardiovascular Diseases, Cause of Death, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Dose-Response Relationship, Drug, Female, Glucosides, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Placebos, Risk Factors, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.